JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M406501200 on August 25, 2004

J. Biol. Chem., Vol. 279, Issue 45, 46882-46889, November 5, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/45/46882    most recent
M406501200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liang, W.
Right arrow Articles by Fishman, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liang, W.
Right arrow Articles by Fishman, P. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Resistance of the Human {beta}1-Adrenergic Receptor to Agonist-induced Ubiquitination

A MECHANISM FOR IMPAIRED RECEPTOR DEGRADATION*

Wei Liang and Peter H. Fishman{ddagger}

From the Membrane Biochemistry Section, Laboratory of Molecular and Cellular Neurobiology, NINDS, National Institutes of Health, Bethesda, Maryland 20892

Down-regulation is a classic response of most G protein-coupled receptors to prolonged agonist stimulation. We recently showed that when expressed in baby hamster kidney cells, the human {beta}1-but not the {beta}2-adrenergic receptor (AR) is totally resistant to agonist-mediated down-regulation, whereas both have similar rates of basal degradation (Liang, W., Austin, S., Hoang, Q., and Fishman, P. H. (2003) J. Biol. Chem. 278, 39773–39781). To identify the underlying mechanism(s) for this resistance, we investigated the role of proteasomes, lysosomes, and ubiquitination in the degradation of {beta}1AR expressed in baby hamster kidney and human embryonic kidney 293 cells. Both lysosomal and proteasomal inhibitors reduced {beta}1AR degradation in agonist-stimulated cells but were less effective on basal degradation. To determine whether {beta}1AR trafficked to lysosomes we used confocal fluorescence microscopy. We observed some colocalization of {beta}1AR and lysosomal markers in agonist-treated cells but much less than that of {beta}2AR even in cells co-transfected with arrestin-2, which increases {beta}1AR internalization. Ubiquitination of {beta}2AR readily occurred in agonist-stimulated cells, whereas ubiquitination of {beta}1AR was not detectable even under conditions optimal for that of {beta}2AR. Moreover, in cells expressing {beta}AR chimeras in which the C termini have been switched, the chimeric {beta}1AR with {beta}2AR C-tail underwent ubiquitination and down-regulation, but the chimeric {beta}2AR with {beta}1AR C-tail did not. Our results demonstrate for the first time that {beta}1AR and {beta}2AR differ in the ability to be ubiquitinated. Because ubiquitin serves as a signal for sorting membrane receptors to lysosomes, the lack of agonist-mediated ubiquitination of {beta}1AR may prevent its extensive trafficking to lysosomes and, thus, account for its resistance to down-regulation.


Received for publication, June 11, 2004 , and in revised form, July 28, 2004.

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{ddagger} To whom correspondence should be addressed: Bldg. 49, Rm. 2A28, 49 Convent Dr., MSC4440, NIH, Bethesda, MD 20892-4440. Tel.: 301-496-1325; Fax: 301-496-8244; E-mail: fishmanp{at}ninds.nih.gov.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J.-G. Li, D. S. Haines, and L.-Y. Liu-Chen
Agonist-Promoted Lys63-Linked Polyubiquitination of the Human {kappa}-Opioid Receptor Is Involved in Receptor Down-Regulation
Mol. Pharmacol., April 1, 2008; 73(4): 1319 - 1330.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. K. Shenoy
Seven-Transmembrane Receptors and Ubiquitination
Circ. Res., April 27, 2007; 100(8): 1142 - 1154.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. J. Gonzalez-Cabrera, T. Hla, and H. Rosen
Mapping Pathways Downstream of Sphingosine 1-Phosphate Subtype 1 by Differential Chemical Perturbation and Proteomics
J. Biol. Chem., March 9, 2007; 282(10): 7254 - 7264.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. M. Tran, J. Friedman, F. Baameur, B. J. Knoll, R. H. Moore, and R. B. Clark
Characterization of beta2-Adrenergic Receptor Dephosphorylation: Comparison with the Rate of Resensitization
Mol. Pharmacol., January 1, 2007; 71(1): 47 - 60.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. T. Drake, S. K. Shenoy, and R. J. Lefkowitz
Trafficking of G Protein-Coupled Receptors
Circ. Res., September 15, 2006; 99(6): 570 - 582.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.